CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Pre-Market Trading 11-22 05:44:58 EST

0.1300

+0.0064

+5.18%

盘前0.1250

-0.0050-3.85%

05:14 EST

High0.1450	Low0.1270	Vol33.64M
Open0.1320	D1 Closing0.1236	Amplitude14.56%
Mkt Cap7.47M	Tradable Cap7.33M	Total Shares57.49M
T/O4.74M	T/O Rate59.66%	Tradable Shares56.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":0.13,"timestamp":1732222800000,"preClose":0.1236,"halted":0,"volume":33636163,"hourTrading":{"tag":"盘前","latestPrice":0.125,"preClose":0.13,"latestTime":"05:14 EST","volume":18644,"amount":2302.28454328,"timestamp":1732270485061},"delay":0,"floatShares":56377299,"shares":57486706,"eps":-86.82832,"marketStatus":"Pre-Market Trading","change":0.0064,"latestTime":"11-22 05:44:58 EST","open":0.132,"high":0.145,"low":0.127,"amount":4739946.87214334,"amplitude":0.145631,"askPrice":0.1411,"askSize":100,"bidPrice":0.125,"bidSize":12402,"shortable":3,"etf":0,"ttmEps":-86.82832,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":0.13,"preHourTrading":{"tag":"盘前","latestPrice":0.125,"preClose":0.13,"latestTime":"05:14 EST","volume":18644,"amount":2302.28454328,"timestamp":1732270485061},"postHourTrading":{"tag":"盘后","latestPrice":0.1276,"preClose":0.13,"latestTime":"19:59 EST","volume":592587,"amount":75689.2193,"timestamp":1732237189456},"volumeRatio":3.848372369329731},"requestUrl":"/m/hq/s/CNSP/wiki","defaultTab":"wiki","newsList":[{"id":"2484675825","title":"CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484675825","media":"ACCESSWIRE","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484675825?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:55","pubTimestamp":1731938100,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.For more information about SNO 2024, please visit the conference website.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggres","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-abstract-accepted-135500390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4135","CNSP","BK4007"],"gpt_icon":0},{"id":"2483711033","title":"CNS Pharmaceuticals Q3 EPS $(0.25) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483711033","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483711033?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:13","pubTimestamp":1731680011,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.12) by 108.33 percent. This is a 99.54 percent increase over losses of $(54.14) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42009099/cns-pharmaceuticals-q3-eps-0-25-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2482367047","title":"CNS Pharmaceuticals Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482367047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482367047?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:31","pubTimestamp":1731339117,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of10cents a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson November 13 (estimated) for the period endi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL8N3MI15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP"],"gpt_icon":0},{"id":"2480258915","title":"CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2480258915","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480258915?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:15","pubTimestamp":1730729700,"startTime":"0","endTime":"0","summary":"Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller. HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment.As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme , the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.The Virtual Investor KOL Connect segment featuring CNS can be accessed here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-virtual-investor-141500687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOL","CNS","BK4135","CNSP","BK4007"],"gpt_icon":0},{"id":"2480183499","title":"CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480183499","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480183499?lang=en_us&edition=fundamental","pubTime":"2024-11-02 00:34","pubTimestamp":1730478857,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  said Friday that a Nasdaq hearings panel has given it more time regain compliance with the exchange's minimum bid price requirement.The company said it was granted until March 11, 2025 to regain compliance with the listing rule.CNS shares were 1.3% higher in recent trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NQmain","LU2210149790.SGD","CNS","IE00BKPKM429.USD","BK4135","BK4588","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BGHQF748.EUR",".IXIC","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","NDAQ","BK4007","CNSP"],"gpt_icon":0},{"id":"2480852858","title":"CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480852858","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480852858?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:00","pubTimestamp":1730466000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggressive and incurab","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-granted-exception-nasdaq-130000273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CNS","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","BK4007","LU2210150020.SGD","BK4588",".IXIC","BK4135","BK4112","CNSP","IE00B3QW5Z07.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2477687495","title":"CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2477687495","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477687495?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:50","pubTimestamp":1729709400,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock  pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share.The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $3 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.A.G.P./Alliance Global Partners is acting as sole placement agent","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-pricing-3-185000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","CNSP","BK4112","BK4135","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD",".IXIC","IE00BGHQF748.EUR","CNS","BK4007","NDAQ"],"gpt_icon":1},{"id":"2477533045","title":"Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2477533045","media":"Benzinga","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477533045?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:50","pubTimestamp":1729691400,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41489449/dow-tumbles-over-250-points-boeing-posts-q3-loss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0868494617.USD","BK4588","BA","LU1883839398.USD","BK4575","LU1430594728.SGD","BK4134","BK4079","MNQmain","VRAX",".IXIC","LU1429558221.USD","LU1435385759.SGD","BK4583","IBM","QLD","LU0321505868.SGD","BK4122","LU2326559502.SGD","PCOM","BK4579","LU1585245621.USD","ANRO","BK4564","SQQQ","BK4007","BK4175","LU1880398471.USD","NQmain","LU0321505439.SGD","BK4551","APVO","BK4538","LU1880398554.USD","LRHC","CNSP","TQQQ","BK4187","BK4533","QID","BK4534","BK4585","PSQ","BK4139"],"gpt_icon":1},{"id":"2474743883","title":"CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2474743883","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474743883?lang=en_us&edition=fundamental","pubTime":"2024-10-10 21:00","pubTimestamp":1728565200,"startTime":"0","endTime":"0","summary":"Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust. HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiform","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participates-virtual-investor-130000621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4135","CNS","CNSP","KOL"],"gpt_icon":0},{"id":"2473201584","title":"CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2473201584","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473201584?lang=en_us&edition=fundamental","pubTime":"2024-10-08 21:15","pubTimestamp":1728393300,"startTime":"0","endTime":"0","summary":"Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET. HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications incl","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participate-2024-healthcare-131500427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4211","BK4007","HCSG","SMMF","BK4135","CNSP","BK4137","VIRI","BK4139"],"gpt_icon":0},{"id":"2469119499","title":"CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2469119499","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469119499?lang=en_us&edition=fundamental","pubTime":"2024-09-23 21:00","pubTimestamp":1727096400,"startTime":"0","endTime":"0","summary":"Webcast presentation on Wednesday, September 25th at 1:55 PM CEST. HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland.In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-present-24th-annual-130000090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FET","CNSP","BK4179","CNS","BK4135","BK4007"],"gpt_icon":0},{"id":"2466270827","title":"CNS Pharmaceuticals - Regains Compliance With Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2466270827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466270827?lang=en_us&edition=fundamental","pubTime":"2024-09-12 21:09","pubTimestamp":1726146576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2466527088","title":"CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2466527088","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466527088?lang=en_us&edition=fundamental","pubTime":"2024-09-12 21:00","pubTimestamp":1726146000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on September 10, 2024, it received notice from The Nasdaq Stock Market LLC  that the Company has regained compliance with the equity requirement under Nasdaq's Listing Rule 5550, subject to Nasdaq Mandatory Panel Monitor related to the equity requirement for a period of one year. Now that the Company has regained compliance with Listing Rule 5550, Nasdaq has advised the Company that this matter is now closed.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-regains-compliance-nasdaq-130000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR",".IXIC","NDAQ","PSQ","BK4585","BK4007","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","QLD","LU2210149790.SGD","LU2095319765.USD","SQQQ","EQR","BK4215","CNS","IE00B64PRP62.GBP","CNSP","TQQQ","BK4135","BK4588","NQmain","IE00BKPKM429.USD","QID","MNQmain"],"gpt_icon":1},{"id":"2466430137","title":"CNS Pharmaceuticals Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2466430137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466430137?lang=en_us&edition=fundamental","pubTime":"2024-09-10 20:56","pubTimestamp":1725972960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 08:56 ET (12:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2466439213","title":"CNS Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2466439213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466439213?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:43","pubTimestamp":1725968618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nFWN3KS11L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2464287033","title":"Ibn Announces Latest Episode of the Biomedwire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2464287033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464287033?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:00","pubTimestamp":1725364804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240903:nTUA9GPP7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2464712870","title":"IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2464712870","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464712870?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:00","pubTimestamp":1725364800,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Sept. 03, 2024  -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823038988.USD","BK4135","BK4535","SG9999004220.SGD","LU0531971678.HKD","LU0251143458.SGD","DBP","CNS","LU0264410563.USD","BK4548","LU0828237940.HKD","LU0143863784.USD","BK4523","LU0066902890.USD","IE00B0JY6M65.USD","IE00B7N09G41.SGD","LU0823039010.USD","BK4207","LU0181495838.USD","LU1102505762.USD","IE00BYTNYM70.SGD","BK4007","CNSP","IBN","BK4588","LU0164881194.USD","LU1868837565.USD","LU1868838027.USD","LU0143863198.USD","BK4585","LU1868837722.USD"],"gpt_icon":0},{"id":"2462955111","title":"CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2462955111","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462955111?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:10","pubTimestamp":1724764200,"startTime":"0","endTime":"0","summary":"Live webcast on Wednesday, August 28th at 3:20 PM ET. HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss recent corporate events at LIVE!with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of se","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participate-live-webull-131000383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CNSP","SIPC","BK4135","CNS"],"gpt_icon":0},{"id":"2461312039","title":"CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2461312039","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461312039?lang=en_us&edition=fundamental","pubTime":"2024-08-22 21:15","pubTimestamp":1724332500,"startTime":"0","endTime":"0","summary":"Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET. Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advance of the segment by emailing cnsp@jtcir.com. HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participate-virtual-investor-131500518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4135","CNSP","BK4007"],"gpt_icon":0},{"id":"2459658922","title":"CNS Pharmaceuticals reports Q2 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459658922","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459658922?lang=en_us&edition=fundamental","pubTime":"2024-08-16 15:04","pubTimestamp":1723791840,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals press release  : Q2net loss was approximately $2.5 million compared to approximately $4.0 million for the comparable period in 2023.As of June 30, 2024, the Company had cash of approximately $1.5 million. Between June 30, 2024 and August 14, 2024, the Company has raised total gross proceeds of approximately $12.4 million of financing, and has sufficient cash to fund its operations through the first quarter of 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140853-cns-pharmaceuticals-reports-q2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CNSP","BK4007","CNS","BK4135"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":0.0934},{"period":"1month","weight":-0.1704},{"period":"3month","weight":-0.3333},{"period":"6month","weight":-0.9876},{"period":"1year","weight":-0.9988},{"period":"ytd","weight":-0.998}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.194164},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000171},{"month":3,"riseRate":0.2,"avgChangeRate":-0.161933},{"month":4,"riseRate":0.4,"avgChangeRate":0.057823},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002034},{"month":6,"riseRate":0.4,"avgChangeRate":-0.170886},{"month":7,"riseRate":0.2,"avgChangeRate":-0.250938},{"month":8,"riseRate":0.4,"avgChangeRate":-0.098088},{"month":9,"riseRate":0,"avgChangeRate":-0.21514},{"month":10,"riseRate":0.2,"avgChangeRate":0.089289},{"month":11,"riseRate":0.6,"avgChangeRate":-0.011077},{"month":12,"riseRate":0,"avgChangeRate":-0.243828}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction